Fig. 1
From: Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer
ROC analysis of miR-526b and miR-655 in DOX responders and non-responders. ROC Plotter, an online database and analysis tool, was used to assess the association of miR-526b and miR-655 expression with DOX response in cancer patients. (A,B) Mean miR-526b expression and receiver operating characteristic (ROC) analysis based on DOX response in all cancer patients. (C,D) Mean miR-526b expression and ROC analysis based on DOX response in breast cancer patients. (E,F) Mean miR-655 expression and ROC analysis based on DOX response in all cancer patients. Samples without progression before the median follow up time were deemed responders and samples with progression before the median follow up time were deemed non-responders. AUC (Area Under the Curve), TPR (True Positive Rate) and TNR (True Negative Rate).
